EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior Uveitis
Links shared publicly online about this topic.
- 1,672total visits
EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior Uveitis
EyeGate Pharma, the leader in non-invasive ocular drug delivery, announces the completion of a Phase II study of its lead product candidate, EGP-437, for the treatment of anterior uveitis. In the
View full resource at medicalnewstoday.com
Most Recently Shared on October 16, 2009 at 3:58 pm By:
EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior Uveitis: EyeGate Pharma, the leader.. http://bit.ly/VdmqB
EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior Uveitis
medicalnewstoday.com — “EyeGate Pharma, a privately held venture-backed pharmaceutical company developing a non-invasive ocular drug delivery platform and ocular therapeutics, announces today the completion of a Phase II” View full resource at medicalnewstoday.com
Most Recently Shared on March 25, 2010 at 8:37 pm By:
EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior Uveitis EyeGate Pharma, a privately held.. http://bit.ly/aS159B
Advertisement
